Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
VBI Vaccines Inc is a biotechnology business based in the US. VBI Vaccines shares (VBIV) are listed on the NASDAQ and all prices are listed in US Dollars. VBI Vaccines employs 127 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $1.53 |
|---|---|
| 52-week range | $1.74 - $4.83 |
| 50-day moving average | $2.47 |
| 200-day moving average | $3.00 |
| Wall St. target price | $7.67 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.26 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.53 from 2022-01-27
| 1 week (2022-01-21) | -12.07% |
|---|---|
| 1 month (2021-12-28) | -30.77% |
| 3 months (2021-10-28) | -49.00% |
| 6 months (2021-07-28) | -50.16% |
| 1 year (2021-01-28) | -53.07% |
|---|---|
| 2 years (2020-01-28) | 8.51% |
| 3 years (2019-01-28) | 1.54 |
| 5 years (2017-01-27) | 3.8 |
| Revenue TTM | $714,000 |
|---|---|
| Gross profit TTM | $-8,107,000 |
| Return on assets TTM | -18.1% |
| Return on equity TTM | -40.7% |
| Profit margin | 0% |
| Book value | $0.62 |
| Market capitalisation | $447.7 million |
TTM: trailing 12 months
We're not expecting VBI Vaccines to pay a dividend over the next 12 months.
VBI Vaccines's shares were split on a 1:40 basis on 1 May 2016. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your VBI Vaccines shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for VBI Vaccines shares which in turn could have impacted VBI Vaccines's share price.
Over the last 12 months, VBI Vaccines's shares have ranged in value from as little as $1.74 up to $4.83. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while VBI Vaccines's is 1.8454. This would suggest that VBI Vaccines's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
VBI Vaccines Inc. , a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901.
Five major factors contribute to the continued bull run of Bitcoin, ARK says, including growing adoption and long-term focus of investors.
Lido’s liquid staking allows investors holding LUNA and less than 32 ETH to reap the rewards of DeFi staking.
Downturns often let you buy fundamentally strong stocks at bargain prices, but mind the fundamentals and consider these 3 rules.
The crypto market wiped out $1.5 trillion in value in just three months.
Bitcoin breached the $40,000 price level and may plummet lower as Russia signals a potential ban.
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
